NORTH CHICAGO, Ill., Oct. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.
NORTH CHICAGO, Ill., Oct. 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than 5,000 respondents in the biotechnology, pharmaceutical and biopharmaceutical industries.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
NORTH CHICAGO, Ill., Oct. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized a new $5 billion stock repurchase program and increased the company's quarterly cash dividend by nearly 17 percent.
AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.4 Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study, in combination with previously presented results from PIONEER I, will contribute to worldwide regulatory filings for an expanded use of HUMIRA. HUMIRA is not currently approved by regulatory authorities for the treatment of HS.
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11, 2014.
NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home.
NORTH CHICAGO, Ill., Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results from a Phase 2 study evaluating the safety and efficacy of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, in combination with two broad-acting chemotherapeutic medicines in patients with non-small cell lung cancer (NSCLC).
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to email alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?